Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.38 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.38 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22807396 | 0.96 | L3MBTL1 (0.38) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL22816059 | 0.84 | ALPL (0.41) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL22807406 | 0.84 | CASP3 (0.40) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL29514685 | 0.84 | CASP3 (0.40) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL22608250 | 0.82 | CASP3 (0.44) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL22816061 | 0.82 | TSHR (0.42) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL22807395 | 0.79 | L3MBTL1 (0.40) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL29514622 | 0.79 | L3MBTL1 (0.40) | CASP3SENP8SENP7SENP6L3MBTL1 | |
| SCHEMBL22816505 | 0.77 | TSHR (0.42) | L3MBTL1ABL1 | |
| SCHEMBL22608567 | 0.77 | L3MBTL1 (0.44) | CASP3SENP8SENP7SENP6L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-23 | — | — | US | disclosed |
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2023-03-16 | — | — | US | disclosed |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | BIOMARIN PHARMACEUTICAL INC. (US) | 2022-07-12 | — | — | US | disclosed |
| EP-3986863-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BioMarin Pharmaceutical Inc. (US) | 2022-04-27 | — | — | EP | disclosed |
| CN-114258390-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2022-03-29 | — | — | CN | disclosed |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2021-06-10 | — | — | US | disclosed |
| WO-2020257487-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | BIOMARIN PHARMACEUTICAL INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| CN-111788187-A | Glycolate oxidase inhibitors for disease treatment | 生物马林药物股份有限公司 | 2020-10-16 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230079913-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CASP3 2910/4885SENP8 2327/4885SENP7 2842/4885 |
| US-20230088214-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CASP3 3148/4885SENP8 2408/4885SENP7 3012/4885 |
| US-11384055-B2 | Glycolate oxidase inhibitors for the treatment of disease | XDH, PNPO, AGXT | CASP3 2910/4885SENP8 2327/4885SENP7 2842/4885 |
| US-20230089374-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CASP3 2910/4885SENP8 2327/4885SENP7 2842/4885 |
| US-20210171474-A1 | GLYCOLATE OXIDASE INHIBITORS FOR THE TREATMENT OF DISEASE | XDH, PNPO, AGXT | CASP3 2910/4885SENP8 2327/4885SENP7 2842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.